Cone rod dystrophy

Cone-rod dystrophy (CRD), also known as cone-rod degeneration or cone-rod retinal dystrophy, is a group of inherited progressive retinal disorders primarily affecting the cone photoreceptors, with subsequent or simultaneous involvement of rod photoreceptors. Cones are responsible for central vision, color perception, and visual acuity in well-lit conditions, while rods mediate peripheral and dim-light vision. CRD is distinguished from the more common rod-cone dystrophies (such as retinitis pigmentosa) by the predominant and earlier involvement of cones over rods. The hallmark symptoms of cone-rod dystrophy include progressive loss of visual acuity, increased sensitivity to bright light (photophobia), impaired color vision (dyschromatopsia), and central visual field defects (central scotomas). As the disease progresses and rod photoreceptors become increasingly affected, patients typically develop night blindness (nyctalopia) and progressive loss of peripheral vision, which can eventually lead to legal blindness. Fundus examination often reveals macular atrophy, sometimes with a characteristic bull's-eye maculopathy pattern, along with peripheral retinal changes including bone spicule-like pigmentation, attenuated retinal vessels, and optic disc pallor. Electroretinography (ERG) characteristically shows a greater reduction in photopic (cone-mediated) responses compared to scotopic (rod-mediated) responses. Cone-rod dystrophies are genetically heterogeneous, with over 30 causative genes identified to date. They can be inherited in autosomal dominant (e.g., GUCY2D, CRX, PITPNM3), autosomal recessive (e.g., ABCA4, RPGRIP1, CNGB3, CDHR1), or X-linked (e.g., RPGR, CACNA1F) patterns. Mutations in ABCA4 are among the most common causes of autosomal recessive CRD. Currently, there is no cure for cone-rod dystrophy. Management is primarily supportive and includes the use of tinted lenses or filters to reduce photophobia, low-vision aids, occupational therapy, and genetic counseling. Gene therapy approaches are under active investigation for several genetic subtypes, and clinical trials are ongoing. Regular ophthalmologic monitoring is essential for disease management and to address complications.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Cone rod dystrophy